IPP Bureau
GSK bets big on oncology with $10.6 billion Nuvalent acquisition
By IPP Bureau - June 10, 2026
Deal brings late-stage lung cancer candidates zidesamtinib and neladalkib into GSK’s portfolio, strengthening its oncology pipeline ahead of key HIV patent expiries
Ten years on, PMSMA continues to shape safer motherhood in India
By IPP Bureau - June 10, 2026
7.5 crore antenatal check-ups and 1.2 crore high-risk pregnancies identified under flagship programme as maternal and neonatal mortality declines
AmMax Bio licenses Lonza’s ADC tech to advance AML candidate AMB-104
By IPP Bureau - June 10, 2026
The company gets access to Lonza’s clinically validated SYNtecan linker-payload platform as it prepares an IND filing for its acute myeloid leukemia therapy in 2027
Merck appoints Clara Sattler de Sousa e Brito and Robert Machinek to key leadership roles
By IPP Bureau - June 09, 2026
Clara Sattler de Sousa e Brito to lead discovery solutions from Q3 2026, while Robert Machinek takes over as Head of Strategy & Business Development
SPI Pharma completes acquisition of Elementis Pharma
By IPP Bureau - June 09, 2026
Deal expands SPI Pharma’s manufacturing footprint in Germany, enhances pharmaceutical ingredient offerings, and reinforces focus on fast-growing digestive health market
Lupin partners with LABORATORIOS ERN to launch Luforbec in Spain
By IPP Bureau - June 09, 2026
Collaboration combines Lupin’s inhaler manufacturing capabilities with ERN’s strong commercial presence to expand access to respiratory care
FUJIFILM reshapes life sciences leadership to accelerate cell therapy and iPSC expansion
By IPP Bureau - June 09, 2026
Tomoyuki Hasegawa has been appointed CEO of FUJIFILM Biotechnologies California
Wegovy pill smashes past 3mn prescriptions in under six months in US
By IPP Bureau - June 09, 2026
The company said Wegovy hit its first one million prescriptions within 12 weeks of availability
Pfizer reports strong mid-stage results for monthly GLP-1 drug berobenatide
By IPP Bureau - June 09, 2026
The company said data from multiple VESPER studies show the peptide delivered meaningful weight loss, favorable tolerability, and the possibility of a first-in-class monthly injection format
Eli Lilly's oral weight-loss drug shows major fat loss across stages of menopause in trials
By IPP Bureau - June 09, 2026
The results come from post-hoc analyses of more than 1,500 women enrolled in the Phase 3 ATTAIN-1 and ATTAIN-2 trials, presented at the American Diabetes Association’s 86th Scientific Sessions
Ayushman Bharat achieves full national coverage as West Bengal gets onboard
By IPP Bureau - June 09, 2026
Nearly 1.43 crore families in West Bengal to benefit as India’s flagship health assurance scheme achieves full national coverage across all States and Union Territories
AstraZeneca reports major Phase III breakthrough in IgA kidney disease trial
By IPP Bureau - June 09, 2026
At 34 weeks, Ultomiris achieved a 43.4% placebo-adjusted reduction in 24-hour urine protein creatinine ratio (UPCR) versus placebo, meeting the study’s key interim endpoint
ShardaCare provides medical support at 30th Pre-UP State Shooting Championship 2026
By IPP Bureau - June 09, 2026
As official healthcare partner, ShardaCare deployed dedicated medical teams, emergency services, and on-site healthcare infrastructure
Barentz opens new pharma hub in Pennsylvania to accelerate growth across North America
By IPP Bureau - June 09, 2026
New Chesterbrook office strengthens customer engagement, partner collaboration, and regional expansion strategy
